Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Department of Family Medicine, University of Jos and Jos University Teaching Hospital, Jos, Nigeria.
PLoS One. 2020 Jul 31;15(7):e0236801. doi: 10.1371/journal.pone.0236801. eCollection 2020.
Adherence to antiretroviral therapy (ART) and retention in treatment programs are required for successful virologic suppression and treatment outcomes. As the number of adolescents living with HIV continues to increase globally, more information about adherence and retention patterns during and through transition from child- to adult-centered care is needed to ensure provision of a high level of care and inform development of targeted interventions to improve patient outcomes in this vulnerable population. In this analysis, we sought to describe long-term trends in adherence, retention, and virologic suppression in adolescents receiving ART at a pediatric HIV clinic in Nigeria through transition to the adult clinic.
The Jos University Teaching Hospital, United States President's Emergency Plan for AIDS Relief (PEPFAR)-funded HIV clinic in Jos, Plateau State, Nigeria.
We conducted a retrospective observational longitudinal evaluation of data that had been collected during the course of care in a large pediatric ART program in Nigeria. We used descriptive statistics to define our patient population and quantify retention from ART initiation through adolescence and transition to adult-centered care. Logistic regression was used to evaluate predictors of loss to follow-up. We used medication possession ratio (MPR) to quantify adherence for each year a patient was on ART. To evaluate adherence and virologic suppression, we measured the proportion of patients with ≥95% MPR and the proportion with virologic suppression (viral load ≤400 copies/mL) within each age cohort, and used bivariate analyses to examine any association between MPR and VL suppression for all person-years observed.
A total of 476 patients received at least one dose of ART as an adolescent (ages 10-19 years). The proportions of patients lost to follow-up were: 11.9% (71/597) prior to adolescence, 19.1% (31/162) during adolescence, and 13.7% (10/73) during transition to adult-centered care. While over 80% of patients had ≥95% medication adherence in all age groups, their viral load suppression rates through adolescence and post-transition were only 55.6%-64.0%. For patients that successfully transitioned to adult-centered care, we observed 87.7% (50/57) retention at month 12 post-transition, but only 34.6% (9/26) viral load suppression.
Our evaluation found considerable proportions of adolescents lost to follow-up throughout the ART program cascade. We also found discrepancies between the proportions of patients with ≥95% MPR and the proportions with VL suppression, suggesting that true medication adherence in this population may be poor. Significant attention and targeted interventions to improve retention and adherence focused on adolescents are needed in order for global programs to achieve 90-90-90 goals.
接受抗逆转录病毒疗法(ART)并坚持治疗方案对于成功抑制病毒和治疗结果至关重要。随着全球感染艾滋病毒的青少年人数不断增加,需要更多有关在儿童期向成人期护理过渡期间和之后的坚持治疗和保留率的数据,以确保提供高水平的护理,并为改善这一弱势群体的患者结局提供有针对性的干预措施。在这项分析中,我们试图描述在尼日利亚 Jos 大学教学医院接受儿科 HIV 诊所治疗的青少年在通过过渡到成人诊所接受 ART 治疗期间,在坚持治疗、保留和病毒学抑制方面的长期趋势。
尼日利亚 Jos 州,由美国“总统防治艾滋病紧急救援计划”(PEPFAR)资助的 Jos 大学教学医院 HIV 诊所。
我们对尼日利亚一个大型儿科 ART 项目的护理过程中收集的数据进行了回顾性纵向评估。我们使用描述性统计数据来定义我们的患者人群,并从开始接受 ART 治疗到青春期和过渡到成人期护理的时间来量化保留率。使用逻辑回归来评估失去随访的预测因素。我们使用药物使用比例(MPR)来量化每个接受 ART 治疗的患者每年的坚持治疗情况。为了评估坚持治疗和病毒学抑制,我们测量了每个年龄组中≥95% MPR 和病毒学抑制(病毒载量≤400 拷贝/ml)的患者比例,并使用双变量分析检查了所有观察到的个体年 MPR 和 VL 抑制之间的任何关联。
共有 476 名患者在青春期(10-19 岁)接受了至少一剂 ART。在青春期之前、青春期期间和过渡到成人期护理期间失去随访的患者比例分别为:11.9%(71/597)、19.1%(31/162)和 13.7%(10/73)。尽管所有年龄组中超过 80%的患者的药物使用比例≥95%,但他们在青春期和过渡后的病毒载量抑制率仅为 55.6%-64.0%。对于成功过渡到成人期护理的患者,我们观察到在过渡后的第 12 个月有 87.7%(50/57)的保留率,但只有 34.6%(9/26)的病毒载量抑制。
我们的评估发现,在整个 ART 方案级联中,相当一部分青少年失去了随访。我们还发现≥95% MPR 患者比例与 VL 抑制比例之间存在差异,这表明该人群的实际药物坚持情况可能很差。需要对青少年进行有针对性的关注和干预,以提高保留率和坚持治疗,从而使全球项目能够实现 90-90-90 目标。